Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options

Contributed by: PR Newswire

Images

PR Newswire associated1

Tags

AlpharmaximAstonStudy

More Like This

PR Newswire associated0

New research by Alpharmaxim applies behavioural science to identify and understand prescribing choices in neurogenerative diseases - and highlights the need to optimise them

Patient, Research and Industry Leaders Propose Biological Definition and First Biological Staging for Parkinson's Disease

PR Newswire associated0

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson's Disease

PR Newswire associated0

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

MRM Health Initiates Clinical Research in Parkinson’s Disease

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey